This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carriers. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.
|Number of pages||5|
|Journal||Journal of Viral Hepatitis|
|Publication status||Published - Jul 1996|
- Hepatitis B virus
- Nucleoside analogue